A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
